Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of RLY-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Relay Therapeutics, Inc.

Relay Therapeutics is focused on transforming drug discovery by visualizing protein motion in high definition, developing new therapeutic candidates with an emphasis on precision oncology and genetic diseases.

msh id	COM:RELAYTX
symbol	RLAY
name	Relay Therapeutics, Inc.
homepage url	https://www.relaytx.com
country	US
sector	Healthcare
industry	Biotechnology
market	STOCKS
employee count	309
crunchbase url	-
linkedin url	-
founders	-

market cap	927.87M
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	-
growth score 28	-
growth score 90	-
growth score 365	-

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	0.3
growth cost of revenue	0.28
growth depreciation and amortization	1.23
growth ebitda	-0.18
growth ebitda ratio	0.94
growth eps	-
growth eps diluted	-
growth general and administrative expenses	0.14
growth gross profit	8.38
growth gross profit ratio	1.4

COM:RELAYTX

Relay Therapeutics

Last Close

4.66

21/11 21:00

Market Cap

927.87M

Beta: -

Volume Today

1.75M

Avg: -

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	404.97M
cost of revenue	404.97M
depreciation and amortization	5.27M
ebitda	-380.58M
ebitda ratio	-14.9
eps	-0
eps diluted	-0
operating expenses	404.97M
operating income	-373M
operating income ratio	-14.6

accounts receivables	306K
capital expenditure	-4.13M
cash at beginning of period	154.37M
cash at end of period	146.44M
inventory	-
working capital ttm	781.05M

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-